[ad_1] GLASGOW, Scotland — The darunavir-based single-drug combination HIV treatment, which includes cobicistat, emtricitabine, and tenofovir alafenamide (Symtuza, D/C/F/TAF) continued to achieve high virological suppression and low rates of failure comparable to …
Read More »Longer-Term Phase III Data Promising for Single-Tablet Symtuza
